(Q45927158)

17 December 2017

title

Open-label memantine in fragile X syndrome. (English)

1 reference

17 December 2017

1 reference

Christopher J McDougle

series ordinal

3

object named as

Christopher J McDougle

1 reference

17 December 2017

Craig A Erickson

1

1 reference

17 December 2017

Jennifer E Mullett

series ordinal

2

1 reference

17 December 2017

language of work or name

English

0 references

publication date

16 July 2009

1 reference

17 December 2017

Journal of Autism and Developmental Disorders

published in

1 reference

17 December 2017

volume

39

1 reference

17 December 2017

issue

12

1 reference

17 December 2017

page(s)

1629-1635

1 reference

17 December 2017

https://scigraph.springernature.com/pub.10.1007/s10803-009-0807-3

exact match

0 references

cites work

Fragile-X mental retardation: molecular diagnosis in Argentine patients.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10803-009-0807-3

The behavioral phenotype in fragile X: symptoms of autism in very young children with fragile X syndrome, idiopathic autism, and other developmental disorders.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10803-009-0807-3

Psychopharmacology in fragile X syndrome--present and future

21 January 2018

1 reference

12 December 2020

Courting a cure for fragile X.

1 reference

12 December 2020

Memantine hydrochloride: pharmacological and clinical profile.

1 reference

12 December 2020

Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome

1 reference

12 December 2020

A pilot open label, single dose trial of fenobam in adults with fragile X syndrome.

1 reference

12 December 2020

Synaptic ionotropic glutamate receptors and plasticity are developmentally altered in the CA1 field of Fmr1 knockout mice

1 reference

12 December 2020

Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence.

1 reference

12 December 2020

Memantine for disruptive behavior in autistic disorder.

1 reference

12 December 2020

Memantine as an example of a fast, voltage-dependent, open channel N-methyl-D-aspartate receptor blocker

1 reference

12 December 2020

Autism diagnostic observation schedule: a standardized observation of communicative and social behavior

1 reference

12 December 2020

Aberrant differentiation of glutamatergic cells in neocortex of mouse model for fragile X syndrome

1 reference

12 December 2020

Reducing glutamate signaling pays off in fragile X.

1 reference

12 December 2020

Fragile X: translation in action

1 reference

12 December 2020

Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial

1 reference

12 December 2020

Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised.

1 reference

12 December 2020

Altered synaptic plasticity in a mouse model of fragile X mental retardation

1 reference

12 December 2020

Autistic behavior, FMR1 protein, and developmental trajectories in young males with fragile X syndrome.

1 reference

12 December 2020

A pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-deficit/hyperactivity disorder combined type

1 reference

12 December 2020

Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders

1 reference

12 December 2020

A double-blind, placebo-controlled study of memantine in the treatment of major depression

1 reference

12 December 2020

Systematic screening for fragile X syndrome in a cohort of 574 mentally retarded children.

1 reference

12 December 2020

A retrospective study of memantine in children and adolescents with pervasive developmental disorders

1 reference

12 December 2020

A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia

1 reference

12 December 2020

Therapeutic implications of the mGluR theory of fragile X mental retardation

1 reference

12 December 2020

Memantine in moderate-to-severe Alzheimer's disease

1 reference

12 December 2020

The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects.

1 reference

12 December 2020

A pilot double-blind treatment trial of memantine for alcohol dependence.

1 reference

12 December 2020

Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability

1 reference

12 December 2020

Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate.

1 reference

12 December 2020

The mGluR theory of fragile X mental retardation

1 reference

12 December 2020

Autism spectrum phenotype in males and females with fragile X full mutation and premutation.

1 reference

12 December 2020

A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders.

1 reference

12 December 2020

10.1007/S10803-009-0807-3

Identifiers

DOI

1 reference

17 December 2017

Dimensions Publication ID

0 references

1 reference

17 December 2017